The TIMING study is an open-label, prospective, multicenter, registry-based, investigator led (academic-driven), non-inferiority, randomized controlled study to establish the efficacy and safety on timing of initiation of NOAC therapy in patients with acute ischemic stroke and atrial fibrillation. The study is led by Uppsala Clinical Research center (UCR) and koordinated by prof Den här e-postadressen skyddas mot spambots. Du måste tillåta JavaScript för att se den.and dr Den här e-postadressen skyddas mot spambots. Du måste tillåta JavaScript för att se den..

The TIMING-study will use the Swedish Stroke Register (Riksstroke) for enrolment, randomization and follow-up; a method called R-RCT. The intervention is the timing of treatment onset. Eligible patients will be randomized within 72 hours (1:1 i.e. equal in the study arms) from stroke onset by the treating physician at the patient’s local hospital. The choice of NOAC (i.e. apixaban, dabigatran, edoxaban or rivaroxaban) after the acute ischemic stroke is at the discretion of the treating physician. If eligible and willing to participate, the patient will be randomly allocated to early (≤4 days) or delayed (≥5-10 days) start of NOAC by a central computer within the Swedish Stroke Register/TIMING infrastructure. The study protocol is published as an open access article in Trials.

Primary outcome, composite

Recurrent ischemic stroke within 90 days, defined as a new focal neurological deficit of sudden onset lasting at least 24 h (or <24 h if following therapeutic intervention, i.e. thrombolysis or thrombectomy, or if the deficit results in death < 24 h), occurring >24 hours after the index ischemic stroke, irrespective of vascular territory and that is not attributable to edema, brain shift, hemorrhagic transformation, intercurrent illness, hypoxia, or drug toxicity.

and/or

Symptomatic ICH within 90 days, defined as a new focal neurological deficit of sudden onset lasting at least 24 h with documented ICH on imaging. Any intraparenchymal hematoma (≥10mm) will be considered, including hemorrhagic transformation of the index ischemic stroke. However microhemorrhages (<10mm) are not considered to be an ICH. ICH will be classified as symptomatic if it is associated with ≥4 points in total NIHSS or ≥2 points in one NIHSS category.

and/or

Death considered as all-cause mortality within 90 days.

Recruitment started in April 2017. Today 33, out of the 72 Stroke Units in Sweden, are participating in TIMING (October 22, 2018).
Read more on www.ClinicalTrials.gov or download (open access) the published study protocol from Trials.

Tillbaka till toppen
Cookies gör att denna webbplats fungerar korrekt. Genom att fortsätta använda webbplatsen godkänner du att vi använder cookies.
Vår policy om cookies och personuppgifter OK